HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Junlebao Dairy Group - The Strength and the Concerns

Pre-IPO SKG Health Technologies - The Industry, the Business and the Concerns

Pre-IPO Henan Kingstar Brewery - The Business, the Concerns and the Outlook

Equity Capital Markets

Inmyshow Digital Technology (Group) / Equity Capital Markets

Inmyshow Digital Technology (Group) (600556 CH)

<ul>
<li>The accumulated data from over a decade of continuous operations form the core competitive barrier. New entrants find it difficult to obtain high-quality data. This is the highest entry barrier.</li>
<li>The concern is as AIGC tools become homogeneous, self-built celebrity marketing system can integrate data at a lower cost, and the technical barriers of Inmyshow face the risk of erosion.</li>
<li>The IPO of HK stocks usually has a discount of 20%-30% compared to A-shares. Considering Inmyshow has weak profitability/high risks in accounts receivable, A/H discount may be close to 35%-45%.</li>
</ul>


The accumulated data from over a decade of continuous operations form the core competitive barrier. New entrants find it difficult to obtain high-quality data. This is the highest entry barrier.
The concern is as AIGC tools become homogeneous, self-built celebrity marketing system can integrate data at a lower cost, and the technical barriers of Inmyshow face the risk of erosion.
The IPO of HK stocks usually has a discount of 20%-30% compared to A-shares. Considering Inmyshow has weak profitability/high risks in accounts receivable, A/H discount may be close to 35%-45%.


Pre-IPO Inmyshow Digital Technology (A/H Listing) - The Business Model and the Concerns Behind